01—Abstract
Summary
Summary of the 10-Q filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. reported a strong second quarter of 2025 in its Form 10-Q filed August 5, 2025.
Total revenues were $325.7 milliona for the three months ended June 30, 2025, up from $231.4 million a year earlier, and $590.6 million for the six months, up from $427.2 million. Royalties were the main driver at $205.6 million for the quarter (up 65%), reflecting continued uptake of DARZALEX SC, VYVGART Hytrulo and Phesgo. Net income was $165.2 million for the quarter, or $1.33 per diluted share, compared with $93.2 million and $0.72 per diluted share a year earlier.
Operating income for the quarter was $202.4 millionb. The balance sheet shows cash, cash equivalents and marketable securities of $548.2 million as of June 30, 2025, against long-term debt, net, of $1.51 billion, which consists of the 2027 and 2028 convertible notes. Stockholders' equity fell to $332.7 million from $363.8 million at December 31, 2024, largely due to share repurchases.
The company repurchased 5.8 million shares in the second quarter for $303.5 millionc, and the six-month cash flow statement shows $303.5 million of repurchases of common stock. Net cash provided by operating activities was $253.9 million for the six months.
The company stated that it believes its current cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next 12 months. The filing also disclosed a patent infringement lawsuit filed in April 2025 against Merck Sharp & Dohme Corp. concerning its MDASE subcutaneous delivery technology, and noted that Merck has challenged certain related U.S. patents in post-grant review proceedings at the PTAB.
02—Key points
Key Highlights
- Total revenues of $325.7 million for Q2 2025, up from $231.4 million in Q2 2024; royalties of $205.6 million rose 65%.
- Net income of $165.2 million, or $1.33 per diluted share, for Q2 2025, versus $93.2 million, or $0.72 per diluted share, a year earlier.
- Six-month operating cash flow of $253.9 million, compared with $185.2 million in the prior-year period.
- Share repurchases totaled $303.5 million in Q2 2025, with 5.8 million shares repurchased at an average price of $52.16; the $750 million program authorized in February 2024 continues with a third $250 million tranche initiated in June 2025.
- Cash, cash equivalents and marketable securities of $548.2 million at June 30, 2025; company states this is sufficient for at least the next 12 months.
- Convertible notes carrying amount of $1.51 billion at June 30, 2025, against $1.525 billion in principal; the revolving credit facility was undrawn.
- Litigation: filed a patent infringement lawsuit against Merck in April 2025 over MDASE technology, with Merck challenging certain related patents at the PTAB.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Halozyme Therapeutics kept $0.51.
- Revenue$325.7M100.0%
- Cost of revenue−$46.4M14.2%
- Gross profit$279.4M85.8%
- Operating costs−$76.9M23.6%
- Operating income$202.4M62.2%
- Interest, other & tax−$37.3M11.4%
- Net income$165.2M50.7%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 5, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $325.72M$231.35M | +40.8% |
| Cost of Revenue | $46.36M$39.61M | +17.0% |
| Gross Profit | $279.36M$191.75M | +45.7% |
| R&D Expenses | $17.54M$21.04M | −16.6% |
| SG&A Expenses | $41.61M$35.71M | +16.5% |
| Operating Expenses | $123.28M$114.12M | +8.0% |
| Operating Income | $202.44M$117.23M | +72.7% |
| Net Income | $165.16M$93.25M | +77.1% |
| EPS (Basic) | $1.36$0.73 | +86.3% |
| EPS (Diluted) | $1.33$0.72 | +84.7% |
| Shares Outstanding (Basic) | 121.34M127.12M | −4.5% |
| Shares Outstanding (Diluted) | 124.16M129.22M | −3.9% |
05—Questions
Frequently Asked Questions
What drove the increase in revenue this quarter?
Royalties were the main driver, rising to $205.6 million from $124.9 million, primarily from continued sales uptake of DARZALEX SC by Janssen, VYVGART Hytrulo by argenx and Phesgo by Roche. Product sales, net rose 3% to $81.5 million, and revenues under collaborative agreements rose 40% to $38.6 million, mainly due to the timing of milestones, including a $10.0 million sales-based milestone.
How is the company returning capital to shareholders?
The company repurchased $303.5 million of common stock in the second quarter of 2025 under its $750 million program authorized in February 2024. The filing states that $196.5 million remained available under the program as of June 30, 2025. Shares outstanding fell to 117.6 million at June 30, 2025, from 123.1 million at December 31, 2024.
What is the company's debt position?
Long-term debt, net, was $1.51 billion at June 30, 2025, consisting of 0.25% Convertible Notes due 2027 and 1.00% Convertible Notes due 2028, with total principal of $1.525 billion. The notes were not convertible as of June 30, 2025, and the company stated it was in compliance with all covenants. The $250 million revolving credit facility was not drawn, and the filing describes a $575 million revolving credit facility.
What legal matters did the company disclose?
In April 2025, Halozyme filed a patent infringement lawsuit against Merck in the U.S. District Court in New Jersey, alleging that Merck used its MDASE technology to develop subcutaneous Keytruda, and it is seeking damages and injunctive relief. Merck has also brought post-grant review proceedings at the PTAB challenging the validity of certain related U.S. patents. The company states these matters are not related to its ENHANZE intellectual property.
06—Continue